FCM showed a significant increase in CD63+ or both CD9+ and CD63+ NLF-EVs of CRS patients compared to HCs (p = 0.1026 for CD9+ EVs; *** p < 0.0002 for CD63+ EVs; *** p = 0.0007 for CD9+/CD63+ EVs) but no significant difference between CRSwNP and CRSsNP patients. This evidence concerns the gene CD9 and chronic rhinosinusitis with nasal polyps.